HVC
LGND icon

Healthcare Value Capital’s Ligand Pharmaceuticals LGND Stock Holding History

Healthcare Value Capital’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-40,075
Closed -$2.85M – 27
2019
Q2 		$2.85M Hold
40,075
– – 5.35% 7
2019
Q1 		$3.14M Buy
+40,075
New +$3.04M 12.11% 5

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Healthcare Value Capital's LGND Position: Q2 2015 in Review

Healthcare Value Capital sold out of Ligand Pharmaceuticals (LGND) in Q2 2015, closing a stake of 80,150 shares — an estimated $3.86M sold.

Healthcare Value Capital first reported a position in LGND in Q3 2014 and held it in 3 quarters. The position peaked at $3.86M in Q1 2015. 215 funds tracked by Wall St. Rank hold LGND as of Q2 2015.

  • Healthcare Value Capital reported no remaining Ligand Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Healthcare Value Capital sold 80,150 Ligand Pharmaceuticals shares in Q2 2015, an estimated $3.86M.
  • Healthcare Value Capital first reported a position in Ligand Pharmaceuticals in Q3 2014 and held it in 3 quarters.
  • Healthcare Value Capital's Ligand Pharmaceuticals position peaked at $3.86M in Q1 2015.
  • 215 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2015.

Based on Healthcare Value Capital's 13F filing for Q2 2015, filed 14 Aug 2015.